ADVOCATE. CONNECT. INNOVATE.

Meet with 5 AM Ventures – San Diego

San Diego, CA

5/30/2018

10:30am - 12:00pm

Driven by the “old-fashioned” VC style of working closely with portfolio companies, 5AM’s portfolio of advanced life science technologies is diversified within the industry’s biopharmaceutical, drug delivery technology and research instrument sectors.

On May 30th, 5AM Ventures will be visiting JLABS in San Diego to provide an overview of their unique hands-on approach to company building and to meet 1-on-1 with pre-selected companies.

*The one-on-one application process is separate from the event registration process. Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due by April 30. Apply Here.

Program Overview:
5AM Ventures is focused on building the next-generation of life science companies. 5AM’s investment professionals employ a time-tested, hands-on approach to company building and they are often directly involved in setting company strategy, management recruiting, business development and fundraising. 5AM is currently funding in Seed and Series A investments out of their 5th Fund at $285M.

Areas of interested include:

Early Stage Therapeutics:Modality and indication agonistic. 5AM focuses on novel biology identifying new targets and pathways to drug for therapeutic effect; and novel modality platforms. 5AM gravitates to pre-clinical opportunities where there are compelling mechanistic, cell, and/or animal model proof of concept data, and invest through pre-clinical and into clinical proof of concept.

Drug Delivery Platforms:Novel ways to deliver drugs that are already on the market, to enhance their safety and/or efficacy profiles, improve health economics, and ultimately improve patient outcomes. These products generally go through the FDA 505(b)(2) regulatory pathway.

Research Tools and Technologies:Technology platforms (instruments and consumables, reagents) that enable novel scientific insights in the research and drug development spaces. Interest areas include genomics and proteomics, synthetic biology, and single cell biology. These are generally research-use-only technologies, though some have line of sight to diagnostic applications as well.

David Allison and Mira Chaurushiya of 5AM Ventures will be in attendance to provide an overview presentation of their firm’s areas of interest. They will be on hand to meet with a handful of applicants 1-on-1 after the presentation. To be considered for a 1-on-1 meeting complete the information required here. Applications due by April 30, 2018.

Speakers:
David Allison | Principal, 5AM Ventures read bio»
Mira Chaurushiya | SeniorAssociate, 5AM Ventures read bio»

Agenda:
10:30AM | Registration and Networking
11:00 AM | Presentation and Q&A
12:00 PM | Networking Lunch
1:00-5:15 PM | One-on-One Meeting* (30 – minute meetings)

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due April 30, 2018. Apply Here.

Fees:
Presentation
$25 | General Public
$35 | Onsite

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Apply to meet one-on-one with David Allison and Mira Chaurushiya of 5AM Ventures. Your application will be reviewed and you will be notified of acceptance on April 30, 2018. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Speakers’ Biographies:
David Allison, Ph.D. | Princiapl, 5AM Ventures
David Allison, Ph.D. joined 5AM Ventures as a Principal in 2016. He was previously a Principal at Versant Ventures, where he focused on biotechnology and other healthcare invest ments, and was involved with companies such as Aprea, BioTie Therapies (acquired by Acorda), Crinetics, Holaira and NeuWave Medical (acquired by Johnson and Johnson). Prior to Versant, Dr. Allison was a Principal at Split Rock Ventures where he was involved with companies such as Ardian (acquired by Medtronic), Histogenics (Nasdaq: HSGX), RF Surgical (acquired by Medtronic), Transcend (acquired by Alcon) and Twelve (acquired by Medtronic). Prior to Split Rock Ventures he was a Sr. Associate at PTV Sciences. David also spent time with SurModics in its diagnostics and drug discovery business unit and as a NSF Research Fellow at The Cleveland Clinic Foundation’s Heart Valve Laboratory. Dr. Allison received a Ph.D. in Bioengineering from Rice University with a focus in Cell Biology and Extracellular Matrix in Cardiovascular Disease. He received a B.S. in Biomedical Engineering from The University of Iowa. Dr. Allison is based in the San Francisco, CA office.

^ Back to speakers’ list ^

Mira Chaurushiya, Ph.D. | Senior Associate, 5AM Ventures
Mira Chaurushiya, Ph.D. is a Senior Associate at 5AM Ventures. Dr. Chaurushiya joined in 2015 from Genentech where she was a Postdoctoral Fellow in the Department of Physiological Chemistry studying mouse models of cancer and stem cells. Prior to Genentech, she completed her Ph.D. work at the Salk Institute, where she studied Herpes Simplex Virus infections and epigenetics. Her work has been published in Science and PNAS, among others. Dr. Chaurushiya currently serves as an Observer on the Boards of Chrono Therapeutics, Precision Nanosystems, Purigen Biosystems, Biodesy, Cleave Biosciences, GenePeeks and Pear Therapeutics. In addition, she is a Fellow of the Society of Kauffman Fellows and serves on the Board of Biotech Connection Bay Area, a non-profit that focuses on career development for academic scientists. Dr. Chaurushiya received a Ph.D. in Biological Sciences from the University of California, San Diego in conjunction with the Salk Institute for Biological Studies, where she was awarded the Martin Kamen Thesis Prize in Biochemistry. She received her B.A. in Biology from Carleton College. Dr. Chaurushiya is based in the San Francisco, CA office.

^ Back to speakers’ list ^

About the Meet With… Series:
The purpose of the Meet with series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA’s Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, OrbiMed, Osage University Partners, Spectrum 28, Quark Venture, and AbbVie Ventures.

Location:
JLABS in San Diego
3210 Merryfield Row
San Diego, California

Click Here for More Information

Contact: Michelle Maiello
Contact Email: mmaiello@its.jnj.com